Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment
Journal of Medicinal Chemistry · 23.07.2026 · 69 (14) · 16834-16877
DOI: 10.1021/acs.jmedchem.6c00487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.07.2026. Verfasst von Weiji Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen 518060, China. Hauptthemen laut MEDLINE: p21-Activated Kinases, Triple Negative Breast Neoplasms, Drug Design, Antineoplastic Agents. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Shenzhen Technology University, Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen 518060, China.
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Ch…
- School of Pharmacy, Shaoyang University, Shaoyang 422000, China.
ORCID-Profile: Dahong Yao
Förderung
- Shenzhen Technology University
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
- Guangdong Province General University Innovation Team Project
- He Zhendan Academician Workstation of Yunnan Province
Zitieren
APA
Chen, W., Cheng, X., Zhao, X., Chen, Z., Lai, Y., Hao, W., He, Z., Lin, W., Wu, Y., Guo, Y., Pan, D., Zhou, L., & Yao, D. (2026). Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry, 69(14), 16834-16877. https://doi.org/10.1021/acs.jmedchem.6c00487
Vancouver
Chen W, Cheng X, Zhao X, Chen Z, Lai Y, Hao W, et al. Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry. 2026;69(14):16834-16877. doi:10.1021/acs.jmedchem.6c00487
BibTeX
@article{Chen2026,
author = {Chen, Weiji and Cheng, Xiaoling and Zhao, Xi and Chen, Zixuan and Lai, Yupei and Hao, Wenli and He, Zhendan and Lin, Wenhong and Wu, Yan and Guo, Yaping and Pan, Dabo and Zhou, Le and Yao, Dahong},
title = {Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {14},
pages = {16834--16877},
doi = {10.1021/acs.jmedchem.6c00487}
}
EUVIMED